Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher L. Cioffi, Andrew Blauvelt
Topics & Concepts
MedicinePlaceboPsoriasisPopulationDosingClinical trialPsoriasis Area and Severity IndexAdverse effectInternal medicineClinical endpointRandomized controlled trialTolerabilityPlaque psoriasisPhysical therapyDermatologyAlternative medicineEnvironmental healthPathologyPsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin Diseases